Completed Business Combination with Big Cypress Acquisition Corp. Common stock to commence trading on the Nasdaq Global Market October 25, 2021, under the ticker symbol “SABS” SIOUX FALLS, S.D...
Big Cypress Acquisition Corp. Stockholders Approve Business Combination with SAB Biotherapeutics Sets Stage for Public Debut of SAB, Whose Unique Immunotherapy Platform Produces Targeted...
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies...
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully human polyclonal antibodies...
第3相への移行は、ヒトのドナーなしで完全ヒト型ポリクローナル抗体を作製するSAB独自のDiversitAb™免疫療法プラットフォームにとって、重要な節目となる成果 第2相で試験したSAB-185の両用量が、事前規定した...
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies...
Der Übergang in die Phase 3 bedeutet einen wichtigen Meilenstein für die einzigartige Immuntherapieplattform von SAB, DiversitAb™ , die vollständig humane polyklonale Antikörper ohne menschliche...
La progression vers la Phase 3 constitue un jalon majeur pour la plateforme unique d'immunothérapie DiversitAb™ de SAB qui produit des anticorps polyclonaux entièrement humains sans donneurs...
Advancement to Phase 3 is major milestone for SAB’s unique DiversitAb™ immunotherapy platform that produces fully-human polyclonal antibodies without human donors Both doses of SAB-185 tested in...
Big Cypress Acquisition Corp Announces Special Meeting of Stockholders to Approve Business Combination with SAB Biotherapeutics Registration Statement on Form S-4 Has Been Declared Effective by...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.